Elotuzumab fails late-stage multiple myeloma trial (ELOQUENT-1)
Combination of elotuzumab plus lenalidomide and dexamethasone vs. lenalidomide and dexamethasone alone in patients with newly diagnosed, previously untreated multiple myeloma who are transplant-ineligible did not meet progression-free survival endpoint
Source:
Biospace Inc.